The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis
We investigated the comparative age-related efficacy of dimethyl fumarate (DMF) and natalizumab (NTZ) in clinical practice on multiple sclerosis (MS). Research in this area is lacking in the previous literature. In a three-year retrospective and clinical-paraclinical study, we compared 173 DMF patie...
Saved in:
Main Authors: | Roberto De Masi (Author), Stefania Orlando (Author), Antonella De Donno (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Natalizumab in the treatment of multiple sclerosis
by: Brandon A Brown
Published: (2009) -
Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab
by: Francesco Patti, et al.
Published: (2009) -
Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations
by: Prosperini L, et al.
Published: (2016) -
Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis
by: Ruggieri S, et al.
Published: (2014) -
Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate
by: Nicholas JA, et al.
Published: (2014)